Long-term eculizumab treatment contributes to recovery from end-stage renal disease caused by atypical hemolytic uremic syndrome

Yuji Yamada, Ryohei Abe, Yutaka Okano, Yoshitaka Miyakawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We experienced a favorable outcome in an adult case of atypical hemolytic uremic syndrome (aHUS) after long-term eculizumab treatment. A 38-year-old Japanese man with a history of central retinal vein occlusion was admitted to our hospital with progressive dyspnea. He was found to have non-immune hemolytic anemia, thrombocytopenia, and acute renal failure two weeks after an episode of the common cold. Plasma exchange was ineffective; therefore, we initiated eculizumab after we excluded other thrombotic microangiopathies. Although long-term peritoneal dialysis was required, we successfully discontinued dialysis 18 months after the onset of aHUS with eculizumab.

Original languageEnglish
Pages (from-to)1085-1088
Number of pages4
JournalInternal Medicine
Volume56
Issue number9
DOIs
Publication statusPublished - 2017 Jan 1

Keywords

  • Atypical hemolytic uremic syndrome
  • Eculizumab
  • Peritoneal dialysis
  • Thrombotic microangiopathy

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Long-term eculizumab treatment contributes to recovery from end-stage renal disease caused by atypical hemolytic uremic syndrome'. Together they form a unique fingerprint.

  • Cite this